complete human endothelial cell medium Search Results


complete human endothelial cell medium  (Cell Systems Corporation)
90
Cell Systems Corporation complete human endothelial cell medium
Azithromycin effectively inhibits lung tumor angiogenesis in vitro and in vivo . (A) Representative images of an in vitro capillary network formation were captured. HTL-ECs together with drugs were plated onto <t>complete</t> Matrigel matrix and capillary networks were formed within 6 h. Magnification, ×50. Scale bar represents 200 µm. (B) Quantification of capillary tube length. Azithromycin significantly inhibits in vitro capillary network formation of HLT-ECs in a dose-dependent manner. (C) Azithromycin potently inhibits VEGF/bFGF induced angiogenesis in vivo . Representative images taken 14 days into an in vivo angiogenesis assay. A mixture of 30 ng/µl of bFGF and 20 ng/µl of VEGF was used. (D) Quantification of angiogenesis using fluorescein isothiocyanate-lectin. These data are derived from three independent experiments. *P<0.05, compared with the control or VEGF/bFGF group. HTL-ECs, <t>human</t> lung tumor-associated <t>endothelial</t> cells; VEGF, vascular endothelial growth factor; bFGF, fibroblast growth factor-basic.
Complete Human Endothelial Cell Medium, supplied by Cell Systems Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/complete human endothelial cell medium/product/Cell Systems Corporation
Average 90 stars, based on 1 article reviews
complete human endothelial cell medium - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human endothelial cell complete growth medium #1001  (ScienCell)
90
ScienCell human endothelial cell complete growth medium #1001
Azithromycin effectively inhibits lung tumor angiogenesis in vitro and in vivo . (A) Representative images of an in vitro capillary network formation were captured. HTL-ECs together with drugs were plated onto <t>complete</t> Matrigel matrix and capillary networks were formed within 6 h. Magnification, ×50. Scale bar represents 200 µm. (B) Quantification of capillary tube length. Azithromycin significantly inhibits in vitro capillary network formation of HLT-ECs in a dose-dependent manner. (C) Azithromycin potently inhibits VEGF/bFGF induced angiogenesis in vivo . Representative images taken 14 days into an in vivo angiogenesis assay. A mixture of 30 ng/µl of bFGF and 20 ng/µl of VEGF was used. (D) Quantification of angiogenesis using fluorescein isothiocyanate-lectin. These data are derived from three independent experiments. *P<0.05, compared with the control or VEGF/bFGF group. HTL-ECs, <t>human</t> lung tumor-associated <t>endothelial</t> cells; VEGF, vascular endothelial growth factor; bFGF, fibroblast growth factor-basic.
Human Endothelial Cell Complete Growth Medium #1001, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human endothelial cell complete growth medium #1001/product/ScienCell
Average 90 stars, based on 1 article reviews
human endothelial cell complete growth medium #1001 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human choroidal microvascular endothelial cell complete medium  (Procell Inc)
90
Procell Inc human choroidal microvascular endothelial cell complete medium
Azithromycin effectively inhibits lung tumor angiogenesis in vitro and in vivo . (A) Representative images of an in vitro capillary network formation were captured. HTL-ECs together with drugs were plated onto <t>complete</t> Matrigel matrix and capillary networks were formed within 6 h. Magnification, ×50. Scale bar represents 200 µm. (B) Quantification of capillary tube length. Azithromycin significantly inhibits in vitro capillary network formation of HLT-ECs in a dose-dependent manner. (C) Azithromycin potently inhibits VEGF/bFGF induced angiogenesis in vivo . Representative images taken 14 days into an in vivo angiogenesis assay. A mixture of 30 ng/µl of bFGF and 20 ng/µl of VEGF was used. (D) Quantification of angiogenesis using fluorescein isothiocyanate-lectin. These data are derived from three independent experiments. *P<0.05, compared with the control or VEGF/bFGF group. HTL-ECs, <t>human</t> lung tumor-associated <t>endothelial</t> cells; VEGF, vascular endothelial growth factor; bFGF, fibroblast growth factor-basic.
Human Choroidal Microvascular Endothelial Cell Complete Medium, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human choroidal microvascular endothelial cell complete medium/product/Procell Inc
Average 90 stars, based on 1 article reviews
human choroidal microvascular endothelial cell complete medium - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Azithromycin effectively inhibits lung tumor angiogenesis in vitro and in vivo . (A) Representative images of an in vitro capillary network formation were captured. HTL-ECs together with drugs were plated onto complete Matrigel matrix and capillary networks were formed within 6 h. Magnification, ×50. Scale bar represents 200 µm. (B) Quantification of capillary tube length. Azithromycin significantly inhibits in vitro capillary network formation of HLT-ECs in a dose-dependent manner. (C) Azithromycin potently inhibits VEGF/bFGF induced angiogenesis in vivo . Representative images taken 14 days into an in vivo angiogenesis assay. A mixture of 30 ng/µl of bFGF and 20 ng/µl of VEGF was used. (D) Quantification of angiogenesis using fluorescein isothiocyanate-lectin. These data are derived from three independent experiments. *P<0.05, compared with the control or VEGF/bFGF group. HTL-ECs, human lung tumor-associated endothelial cells; VEGF, vascular endothelial growth factor; bFGF, fibroblast growth factor-basic.

Journal: Oncology Letters

Article Title: Azithromycin effectively inhibits tumor angiogenesis by suppressing vascular endothelial growth factor receptor 2-mediated signaling pathways in lung cancer

doi: 10.3892/ol.2017.6103

Figure Lengend Snippet: Azithromycin effectively inhibits lung tumor angiogenesis in vitro and in vivo . (A) Representative images of an in vitro capillary network formation were captured. HTL-ECs together with drugs were plated onto complete Matrigel matrix and capillary networks were formed within 6 h. Magnification, ×50. Scale bar represents 200 µm. (B) Quantification of capillary tube length. Azithromycin significantly inhibits in vitro capillary network formation of HLT-ECs in a dose-dependent manner. (C) Azithromycin potently inhibits VEGF/bFGF induced angiogenesis in vivo . Representative images taken 14 days into an in vivo angiogenesis assay. A mixture of 30 ng/µl of bFGF and 20 ng/µl of VEGF was used. (D) Quantification of angiogenesis using fluorescein isothiocyanate-lectin. These data are derived from three independent experiments. *P<0.05, compared with the control or VEGF/bFGF group. HTL-ECs, human lung tumor-associated endothelial cells; VEGF, vascular endothelial growth factor; bFGF, fibroblast growth factor-basic.

Article Snippet: Primary HLT-EC was purchased from Cell Biologics, Inc. (Chicago, IL, USA) and grown in Complete Human Endothelial Cell Medium (Cell Systems Corporation, Kirkland, WA, USA).

Techniques: In Vitro, In Vivo, Angiogenesis Assay, Derivative Assay

Effects of azithromycin on various biological functions of HLT-ECs. (A) Azithromycin does not affect VEGF-induced HLT-ECs migration. (B) Azithromycin potently suppresses HLT-EC adhesion and spreading to 10X diluted complete Matrigel. Representative images of a HLT-EC spreading assay were captured. Magnification, ×20, scale bar represents 20 µm. Complete spreading was observed in control cells well-spread in a radial manner and stretched on the surface. (C) Azithromycin inhibits VEGF-stimulated proliferation of HLT-ECs and (D) induces apoptosis of HLT-ECs in the presence of VEGF. VEGF (20 ng/ml) was used in all experiments. These data are derived from four independent experiments. *P<0.05, compared with the VEGF/bFGF group. HTL-ECs, human lung tumor-associated endothelial cells; VEGF, vascular endothelial growth factor; bFGF, fibroblast growth factor-basic.

Journal: Oncology Letters

Article Title: Azithromycin effectively inhibits tumor angiogenesis by suppressing vascular endothelial growth factor receptor 2-mediated signaling pathways in lung cancer

doi: 10.3892/ol.2017.6103

Figure Lengend Snippet: Effects of azithromycin on various biological functions of HLT-ECs. (A) Azithromycin does not affect VEGF-induced HLT-ECs migration. (B) Azithromycin potently suppresses HLT-EC adhesion and spreading to 10X diluted complete Matrigel. Representative images of a HLT-EC spreading assay were captured. Magnification, ×20, scale bar represents 20 µm. Complete spreading was observed in control cells well-spread in a radial manner and stretched on the surface. (C) Azithromycin inhibits VEGF-stimulated proliferation of HLT-ECs and (D) induces apoptosis of HLT-ECs in the presence of VEGF. VEGF (20 ng/ml) was used in all experiments. These data are derived from four independent experiments. *P<0.05, compared with the VEGF/bFGF group. HTL-ECs, human lung tumor-associated endothelial cells; VEGF, vascular endothelial growth factor; bFGF, fibroblast growth factor-basic.

Article Snippet: Primary HLT-EC was purchased from Cell Biologics, Inc. (Chicago, IL, USA) and grown in Complete Human Endothelial Cell Medium (Cell Systems Corporation, Kirkland, WA, USA).

Techniques: Migration, Derivative Assay